MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
Healthcare
$10.22 -2.87%
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
52W Low $6.80High $76.00
Volume 0.01M
Average 0.05M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$12.49M
FY 2025 · Annual
Net Income
-$12.49M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Gross Profit | (77.96K) | (121.75K) | (204.62K) | (215.44K) | (181.75K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.97M | 23.12M | 15.49M | 6.34M | 5.76B |
| Selling, General & Admin | 4.56M | 7.71M | 7.43M | 4.1M | 6.73B |
| Operating Expenses | 18.53M | 30.83M | 22.72M | 10.43M | 12.31M |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| EBITDA | (27.7M) | (27.87M) | (22.25M) | (10.57M) | (12.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (18.61M) | (30.95M) | (22.92M) | (10.65M) | (12.49M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.43K | 253.32K | 463.26K | 172.57K | 180.25K |
| Interest Expense | 2.43M | 253.32K | 0 | 0 | 0 |
| Other Income / Expenses | (11.61M) | 2.96M | 463.25K | (134.56K) | (6.96K) |
| Income Before Tax | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (9.03) | (8.31) | (6.54) | (2.90) | (2.93) |
| EPS (Diluted) | (9.03) | (8.31) | (6.54) | (2.80) | (2.93) |
| 3.35M | 3.37M | 3.44M | 3.74M | 4.27M | |
| 3.35M | 3.37M | 3.44M | 3.86M | 4.27M |
INKT Earnings Waterfall · TTM
NASDAQ:INKT · Revenue to Net Income
Key Ratios
EPS$-2.83
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$12.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.83, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 2, 2026 |
How much revenue does INKT generate?
MiNK Therapeutics, Inc. (INKT) reported $0.00 of revenue in fiscal 2025.
Is INKT profitable?
MiNK Therapeutics, Inc. (INKT) reported -$12.49M of net income.
Continue the stock analysis
Jump to another research area for this company.